Compelling Efficacy Demonstrated in Phase 3 VICTORIA-1 Cohort

Celcuity (CELC) successfully presented the results of its Phase 3 VICTORIA-1 trial at the American Society of Clinical Oncology (ASCO) 2026, focusing on patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer who have a PIK3CA mutation. The trial evaluated a triplet combination therapy (gedatolisib + palbociclib + fulvestrant) and demonstrated a median progression-free survival (mPFS) of 11.1 months, compared to 5.6 months for the current standard of care (alpelisib + fulvestrant), reducing the risk of disease progression or death by 50% (HR=0.50, p<0.0001). The doublet combination therapy also achieved an mPFS of 11.3 months (HR=0.51, p=0.0013), demonstrating potent efficacy in patients with mutations.

Improved Safety and Convenience Compared to Existing Treatments

Extending survival in breast cancer patients is crucial, but maintaining quality of life through safety is equally important. Gedatolisib has demonstrated excellent tolerability. Novartis' Piqray, a current treatment, has a high rate of treatment discontinuation due to severe hyperglycemia and diarrhea. In contrast, the gedatolisib combination therapy showed a discontinuation rate of 2.6% for the triplet regimen and 3.8% for the doublet regimen, a 50% reduction compared to the control group of 7.1%. This lower discontinuation rate helps patients continue treatment without interruption, which is a key factor in increasing physician preference.

Expansion Strategy Targeting a $10 Billion Breast Cancer Market

The overall HR+/HER2- metastatic breast cancer market is approximately $10 billion, with about 40% of patients having a PIK3CA mutation. Celcuity has already submitted a New Drug Application (NDA) for patients without the mutation and is awaiting the FDA's Priority Review (PDUFA) decision on July 17, 2026. The data from the mutated cohort presented at ASCO 2026 will serve as strong evidence for a subsequent New Drug Application (sNDA) to expand the indication. If approved, Celcuity will secure broad market dominance, covering all patients regardless of mutation status.

Intensifying Market Competition and Financial Impact of the Pfizer Licensing Agreement

However, market competition is intense, with Roche's Itovebi gaining FDA approval in October 2024 and establishing itself as a leading competitor. Celcuity entered into a licensing agreement with Pfizer in April 2021, receiving an upfront payment of $10 million and potential milestone payments totaling $330 million. Upon successful commercialization, Celcuity will pay royalties to Pfizer based on a low-to-mid-teen percentage of sales. Therefore, it is crucial for Celcuity to outperform Roche's Itovebi and other competitors in terms of market share and maximize profitability. From an investor's perspective, it is important to closely monitor the market penetration and partnership strategy of the drug to be launched, in addition to the short-term positive impact of the clinical success.